Dr. Laurel Williams

Dr. Laurel Williams

In an effort to improve outcome for dogs diagnosed with OSA, canine osteosarcoma current research is underway at the NC State VTH. Clinical studies evaluating new treatment approaches are under the direction of Dr. Laurel Williams. Osteosarcoma is the most common bone cancer in dogs. Tumors are locally invasive and have a high rate of metastasis.

The first study (Start Date: 1/28/2011 – End Date: 2/28/2012) evaluates dogs with osteosarcoma, treated with amputation and afterward receive Palladia™, a long-term oral medication. Palladia is able to disrupt the blood supply to cancer cells. Because of this, the drug may delay or prevent metastasis which inherently relies on an intact blood supply.

Dogs eligible to be recruited for this study must have a diagnosis of OSA, undergo amputation, and begin Palladia™ five days following surgery. Patients are to return to the VTH each month for a physical exam and blood work. Thoracic X-rays will be performed every two months. The study covers the costs of Palladia™ and blood tests performed to monitor the drug. The client is to pay for the initial evaluation, the amputation, and recheck visits with thoracic radiographs.

The second study is in collaboration with researchers at Ohio State University. This investigation is evaluating dogs with OSA treated with amputation, standard carboplatin chemotherapy, and one of two long-term oral treatment protocols aimed at disrupting the blood supply to cancer cells. Carboplatin drug is provided at no cost and clients also receive a stipend of $50 to 75 for associated lab tests during each study visit.

Owners or veterinarians interested in either one of the two studies can call study coordinator Julie Nettifee Osborne at (919) 513-6812 or or Hamilton, Xandi at (919) 513-6388 or email julie_osborne@ncsu.edu

 

Filed under: Canine Osteosarcoma Mainstream Research

Like this post? Subscribe to my RSS feed and get loads more!